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Abstract
Purpose: To analyse and compare the costs of hepatic tumor ablation with computed tomography (CT)-guided
high-dose rate brachytherapy (CT-HDRBT) and CT-guided radiofrequency ablation (CT-RFA) as two alternative
minimally invasive treatment options of hepatocellular carcinoma (HCC).
Materials and methods: An activity based process model was created determining working steps and required
staff of CT-RFA and CT-HDRBT. Prorated costs of equipment use (purchase, depreciation, and maintenance), costs
of staff, and expenditure for disposables were identified in a sample of 20 patients (10 treated by CT-RFA and 10 by
CT-HDRBT) and compared. A sensitivity and break even analysis was performed to analyse the dependence of costs
on the number of patients treated annually with both methods.
Results: Costs of CT-RFA were nearly stable with mean overall costs of approximately 1909 €, 1847 €, 1816 € and
1801 € per patient when treating 25, 50, 100 or 200 patients annually, as the main factor influencing the costs of
this procedure was the single-use RFA probe. Mean costs of CT-HDRBT decreased significantly per patient ablation
with a rising number of patients treated annually, with prorated costs of 3442 €, 1962 €, 1222 € and 852 € when
treating 25, 50, 100 or 200 patients, due to low costs of single-use disposables compared to high annual fix-costs
which proportionally decreased per patient with a higher number of patients treated annually. A break-even
between both methods was reached when treating at least 55 patients annually.
Conclusion: Although CT-HDRBT is a more complex procedure with more staff involved, it can be performed at
lower costs per patient from the perspective of the medical provider when treating more than 55 patients compared
to CT-RFA, mainly due to lower costs for disposables and a decreasing percentage of fixed costs with an increasing
number of treatments.
Keywords: CT guidance, High-dose rate brachytherapy, Radiofrequency ablation, Cost analysis, Liver, Minimally invasive
treatment
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Key points
 From the perspective of a healthcare provider,
CT-guided high-dose rate brachytherapy (CT-
HDRBT) of HCC is less expensive to perform
than the standard therapy of CT-guided radiofre-
quency ablation (CT-RFA) when treating only a
relatively small number of 55 patients annually
 The cost advantage of CT-HDRBT is mainly based
on the much lower cost of disposables compared
with the high costs of probes for CT-RFA
 The personnel involvement is higher for CT-HDRBT,
but extra staff costs are negligible compared to the
costs of disposables for CT-RFA
Introduction
The use of hepatic tumor ablation has significantly in-
creased during the past two decades, especially for the
treatment of hepatocellular carcinoma (HCC) [1, 2]. In
the treatment guidelines developed by the Barcelona
Liver Clinic Cancer Group (BCLC), tumor ablation is
defined as the primary treatment method in patients
with very early and early stage HCC (BCLC 0 & A) [3].
As the incidence of HCC is rising and life expectancy
in general is increasing, so the amount of patients
undergoing tumor ablation will increase further.
Currently radiofrequency ablation (RFA) is the most
commonly used ablation method [4]. However, RFA has
several limitations, like size limitations, the heat-sink effect
when tumor masses are close to cooling vessels resulting
in incomplete ablation localization underneath the dia-
phragm or close to the liver hilum [5]. As an alternative,
computed-tomography-guided high-dose rate brachyther-
apy (CT-HDRBT) as ablation technique using gamma-
irradiation by an iridium-192 source has been developed,
with very promising results published, comparable to those
of CT-RFA in terms of local tumor control and overall
survival [6, 7].
Health care organizations and policy makers are in-
creasingly interested in the costs of health care, leading
e.g. to the implementation of diagnosis related groups
(DRG) for reimbursement of hospitals in an increasing
number of countries [8] and evidenced by many cost-
benefit and cost-effectiveness investigations [9].
Activity based cost analysis (ABC), originally invented
by Cooper and Kaplan [10], has been used in many ser-
vice organizations and achieved great benefit when
planning activity and budget, because costs can be allo-
cated precisely to their resources and cost factors of ac-
tivities that form the product [9]. Undisputed, optimal
utilization and economic evaluation of limited health
care resources is needed and should be based on reli-
able cost accounting [9].
Therefore, the purpose of this study was to analyse the
costs of both ablation techniques and to identify cost fac-
tors of the two different procedures. This mainly on the
background that CT-RFA is typically performed by inter-
ventional radiology alone whereas the newer method of
CT-HDRBT has to be performed as an interaction of
interventional radiologists and radiation oncologists.
Materials and methods
Definition and determination of costs
This study concentrates on the costs of activities in the
interventional radiology unit and the radiation oncology
department in a German university hospital. The over-
head costs for the hospital, wards and the whole radi-
ology unit were not included.
The cost evaluation was based on the recommenda-
tions on trial design provided by the International Soci-
ety for Pharmacoeconomics and Outcomes Research
(ISPOR) [11, 12].
The information concerning costs was based on the
purchase prices provided by the hospital controlling de-
partment and the effective consumption documented in
the department’s documentation system (GE Centricity
RIS™, Fairfield, CT, USA). The local ethical committee
approved the study protocol (EA1/144/11).
Staff costs were derived from standard personnel rates
provided by the German scientific society (Deutsche For-
schungsgemeinschaft, DFG) [13] as costs per minute for
the different personnel groups. We assumed 40 working
hours/week, 30 days of annual holidays, 15 days mean
absenteeism [14] and 9 days of public holidays. We estab-
lished process models of all steps required in each of the
two ablation procedures of any staff member (interven-
tional radiologist, radiation oncologist, medical physics
expert, technologists, nurses, Table 1). For each step the
duration of involvement was documented in minutes with
calculation of mean values. For both treatment techniques,
we differentiated between the time for the actual interven-
tion and the time for pre- and post- interventional process
steps. The length of the interventional procedure for each
patient was calculated retrospectively from the documented
DICOM headers of the CT imaging data for therapy guid-
ance. Mean time values (in minutes) for all staff involved in
the pre- and post-interventional phases were measured
prospectively by documenting the duration of all steps
during further ongoing RFA- and HDBRT treatments. The
involvement times of the different process steps of all
personnel groups were multiplied with their costs per mi-
nute. Overall staff costs were then calculated as the sum of
costs for the different steps in both treatment pathways.
Cost for equipment usage included purchase costs, de-
preciation, and maintenance costs (Table 2). Prorated
costs were calculated on the basis of a 7-year use and
linear depreciation according to German tax law for the
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Table 1 Procedural steps and involvement staff of both ablation methods
CT-HDRBT CT-RFA
Minutes StaffCode Minutes Staff Code
Preparation
Patient registration 3 ± 0.7 TECH 3 ± 0.63 TECH
Preparation of sterile intervention table 8 ± 1.2 N
Preparation of sterile intervention table, instruments, and RFA device 12 ± 1.41 N
Patient positioning, unenhanced localizer scan 8a ± 1.6 TECH 12a ± 0.89 TECH
N N
Placement of sterile drapes & disinfection 10a ± 1.2 N 10a ± 1.41 N
TECH TECH
Review of images, final check-up 5 ± 1.1 INT-RAD 5 ± 0.63 INT-RAD
CT-Intervention
Induction of conscious sedation 3a ± 0.5 PHYS 3a ± 0 PHYS
N N
TECH
Instrument guidance and positioning of brachytherapy catheters 14a ± 2.4 INT-RAD
N
TECH
Instrument guidance and positioning of RFA probe 14a ± 0.89 INT-RAD
N
TECH
RFA treatment 22a ± 4.56 INT-RAD
N
TECH
Contrast-enhanced CT scan + assessment 5a ± 0.7 INT-RAD 5a ± 0.63 INT-RAD
N N
TECH TECH
Patient monitoring during intervention and postprocedural scan 19 ± 2.7 PHYS 44 ± 4.73 PHYS
Transfer to brachytherapy suite 10 ± 1.2 PHYS
N
Radiotherapy planning 15 ± 1.5 INT-RAD
RO
MPE
Radiotherapy 25 ± 6.2 MPE
Patient monitoring during radiotherapy 25 ± 6.2 PHYS
N
Postprocedural Management
Retraction of brachytherapy catheters, tract sealing, and removal of sterile drapes 10 ± 1.5 PHYS
N
Removal of sterile drapes and transfer to recovery room 7 ± 1.26 PHYS
TECH
N
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CT-scanner, afterloading source, RF-heat-generator and
the radiation planning workstation. The proportionate
costs of the iridium-192 source were calculated based on
the service contract with the vendor, which includes a
regular source change every 8 weeks and necessary soft-
ware updates of the radiation planning workstation.
Depreciation period for the radiation room was 30 years.
Total annual use of equipment, maintenance costs,
and the length of each specific examination were deter-
mined, and based on these data proportionate costs per
minute were calculated. Calculated usage of the CT-
scanner was 200,000 min per year.
Times of usage of the equipment for the specific pa-
tient were measured and included in the calculation.
The total costs were computed by addition of costs for
the use of equipment, staff costs, and expenditure for dis-
posables and are reported as mean values and standard
deviations. For simplification we did not take costs for use
of rooms other than the radiation room, for cleaning, and
for energy into account.
Sensitivity and break-even analysis
A model was created calculating theoretical costs per
patient depending on a variation of the number of pa-
tients treated each year. In this model we assumed a
utilization of the devices exclusively for the investigated
indication – hepatic tumor ablation. Staff costs, the costs
for disposables, and costs for CT were calculated as fixed
Table 1 Procedural steps and involvement staff of both ablation methods (Continued)
Transfer to recovery room 10 ± 1.5 PHYS
N
Monitoring in recovery room 90 ± 11.1 N 90 ± 6.32 N
Documentation and clearance 8 ± 1.4 TECH 8 ± 1.4 TECH
Writing report 5 ± 0.8 INT-RAD 5 ± 0.8 INT-RAD
PHYS physician experienced in conscious sedation and for monitoring of the patient, N nurse, TECH technical assistant, INT-RAD interventional radiologist, MPE
medical physics expert, RO radiation oncologist
aCT blocked for this time period plus additional 10 min for room cleaning etc. Time needed for intervention and ablation were extracted from institutional PACS
data for all patients. All other data were measured in a sample of 5 patients
Table 2 Expenditures for disposables used in CT-RFA and CT-HDRBT
Material type n Costs per unit (in EUR)
CT-guided RFA
Set of sterile drapes and coats 1 34 34
Sterile gloves 2 1.48 2.96
Local anesthetic 1 1.56 1.56
RFA probe 1 1460 1460
Contrast medium 1 16 16
Fentanyl 1 0.65 0.65
Midazolam 1 0.35 0.35
Total costs (in EUR) 1515.12
CT-HDRBT
Set of sterile drapes and coats 1 34 34
Sterile gloves 2 ± 0.43 1.48 3.31 ± 0.64
Local anesthetic 1 1.56 1.56
Puncture cannula 1 22 22
Guide wire 1 23 23
Angiography sheaths 2 ± 0.6 23 42.93 ± 14.46
Brachytherapy catheter 2 ± 0.6 19 35.46 ± 11.95
Fentanyl 1 0.65 0.65
Midazolam 1 0.35 0.35
Gelfoam 1 7.80 7.80
Total costs (in EUR) 187.07 ± 27.05
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costs per patient. The annual equipment costs for the RF-
generator on the one hand or costs for the afterloading
source plus annual depriciation costs of the radiation
room on the other were allocated to an assumed annual
number of patients. Example values for both methods
were calculated and compared for an annual number of
25, 50, 100 and 200 patients treated.
Patient population
During the intervention of 10 patients (7 men, 3 women;
mean age 67.5 ± 5.1) who were treated with CT-guided
RFA and 10 patients (8 men, 2 women; mean age 69.3 ±
6.2 years) who underwent CT-HDRBT working steps
and time involvement of all participants were recorded.
All patients had single HCC target lesions below the size
of 3 cm. Uni- and multivariate analysis comparing age,
sex, tumor size, tumor location and surround etiology
did not show any significant differences between both
groups of patients.
Before any ablation of the liver performed at our hos-
pital the lesions had been classified as unresectable by
consensual decision of the institutional interdisciplinary
tumor board or if patients rejected a possible resection.
The day before the intervention written informed consent
was obtained from each patient after extensive explanation
of the treatment procedure, possible complications, and
alternative treatment options. The local institutional review
committee approved the study.
Method of CT-HDRBT
All patients were treated under conscious sedation using
3–5 mg midazolam (Dormicum™, Hoffmann-La Roche
AG, Basel, Switzerland) and 75–200 μg fentanyl (Fen-
tanyl™, Rotexmedica, Trittau, Germany) and monitored
by a physician experienced in conscious sedation (PHYS,
Table 1) [15, 16]. Dose was adapted individually as re-
quired by the patient.
Procedure of CT-HDRBT has been explained extensively
elsewhere [6, 15, 16], however, we summarize briefly the
working steps of the involved staff: After a spiral scan of
the upper abdomen, performed by a radiological techni-
cian (TECH), a nurse (N) covered the patient with sterile
drapes and disinfected the puncture site. After additional
local anesthesia and a point-shaped skin incision, 6-French
angiographic sheaths (Cordis Avanti + 6F Sheath™, Cordis
Cooperation, Bridgewater, NJ, USA) were inserted into
the hepatic target lesions by an interventional radiologist
(INT-RAD) using the Seldinger’s technique (17 Gauge (G)
Puncture Needle, KLS Martin, Umkirch, Germany, and a
145 cm stiff guidewire, Amplatz Super Stiff™, Boston Sci-
entific, Natick, MA, USA ). They served as stabilization
devices for the closed-ended 6F afterloading catheters
(Primed, Halberstadt, Germany) which were introduced
subsequently. Catheter positions in relation to the hepatic
lesions were depicted on a contrast-enhanced CT scan
that was also used for further treatment planning on a
three-dimensional (3D) radiation planning workstation
(Brachyvision™, Varian Medical Systems, Palo Alto, CA,
USA; Fig. 1). A medical physics expert (MPE), a radiation
oncologist (RO) and the interventional radiologist planned
subsequent radiation. The MPE coordinated the handling
and insertion of the iridium-192 source (Gammamed 12i™,
Varian Medical Systems, Palo Alto, CA, USA). Patients
were transferred to the brachytherapy suite under con-
scious sedation, monitored and accompanied by a phys-
ician and a nurse. During retraction of the catheters, the
puncture tracts were sealed with resorbable thrombogenic
material (Gelfoam™, Pfizer Inc., NY, USA) to minimize the
risk of bleeding. After transfer back to the department’s
recovery room patients were surveyed for approx. 90 min
before being transferred to the department’s ward.
Method of CT-RFA
All patients were treated under conscious sedation using
fentanyl and midazolam monitored by a physician expe-
rienced in conscious sedation (PHYS, Table 1), in the
same way as conscious sedation was induced during CT-
HDRBT. After a spiral scan of the upper abdomen includ-
ing the whole liver, performed by a radiological technician
(TECH), a nurse (N) covered the patient with sterile drapes
Fig. 1 Magnetic resonance imaging scan of a 69-year-old patient with liver cirrhosis and hepatocellular carcinoma in liver segment III (a, arrow).
The tumor was treated by CT-guided high-dose rate brachytherapy with a single catheter and a tumor-enclosing target dose of 20 Gy (b).
Six weeks later, complete tumor ablation is indicated by a surrounding lack of uptake of hepatocyte-specific contrast medium (Primovist™,
Bayer Healthcare, Leverkusen, Germany) (c, arrow)
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and disinfected the puncture site. Local anesthesia was ad-
ministered in the region of the planned puncture site
(Xylonest 0.5 %, AstraZeneca, Wedel, Germany). After a
point-shaped stab skin incision, the ablation probe was ad-
vanced into the hepatic tumor under CT fluoroscopic guid-
ance (RITA Starburst™, RITA Medical Systems, Fremont,
CA, USA) by an experienced interventional radiologist
(INT-RAD). Tumors were ablated according to the ven-
dor’s recommendations using 90–150 W (Generator
Model 1500, RITA Medical Systems, Mountain View,
USA) [17]. After ablation of the target lesion, the probe
was switched to the tract ablation mode to ablate the tract
during retraction of the probe. To assess whether complete
ablation of the target lesion was accomplished, a contrast-
enhanced spiral CT scan was performed (120 ml Ultravist™
370, Bayer Healthcare, Leverkusen, Germany, Fig. 2). A
nurse monitored all patients for 90 min after the interven-
tions in the recovery room before they were transferred to
the department’s ward.
Results
Workings steps and staff involved for CT-HDRBT and
CT-RFA procedures and their durations are listed in
Table 1. Calculated staff costs per minute (in EUR) were
0.874 € for a physician, for the medical physics expert
0.516 € and 0.455 € for a nurse or technologist. Based on
the staff involvement times presented in Table 1, average
staff costs summed to 252.80 ± 19.65 € per patient for CT-
HDRBT (mean total duration: 277 min) and to 211.36 ±
15.42 € per patient for CT-RFA (mean total duration:
242 min).
Counting as variable disposable costs, the mean num-
ber of brachytherapy catheters per patient was 2 ± 0.6
for CT-HDRBT treatment and 1 probe per patient for
RFA treatment. Expenditure for disposables summed up
to 187.07 ± 27.05 € per patient for CT-HDRBT and
1,515.12 € ± 0 per patient for RFA (Table 2).
All these costs were independent from the number pa-
tients treated.
Proportionate costs for equipment were strongly
dependent on the number of patients treated annually by
each method (Table 3). Fix costs which had to be allocated
to the number of patients were 74,019.05 € for CT-
HDRBT and 3,098.57 € for CT-RFA.
Total costs per intervention for the 25, 50, 100 or 200 pa-
tients treated annually were 1,909.52€, 1,847.55 €, 1,816.57
€ and 1,801.07 € for CT-RFA whereas 3,442.85 €, 1,962.47
€, 1,222.27 € and 852.18 € were calculated for CT-HDRBT.
Figure 3 illustrates these different cost characteristics
of both methods, with a break-even for CT-HDRBT at
55 patients.
Discussion
Local tumor ablation has become an important part in
the treatment of oncologic patients, especially patients
with HCC. Various techniques for local therapies have
been established, but only few cost identifications have
been performed [18] and this is the first one using an
ABC analysis.
ABC accounting was originally designed for use in in-
dustry and service production units, and has been found
to serve well in health care service units [9, 19]. RFA
and CT-HDRBT are competing ablation methods for the
treatment of HCC. Both treatments have become estab-
lished in clinical routine and have shown to be safe and
effective in terms of local tumor control and prolonging
patient survival [6, 15, 20, 21].
In any health care system resources are limited, and
therefore the most cost-effective method should be used
when there are two competing methods with comparable
clinical outcome, as far as single arm studies in the litera-
ture can be compared. However, no randomized trial
comparing both methods has so far been performed to in-
vestigate therapeutic differences as direct comparison.
We found in our model that the more complex method
of HDBRT can be performed at lesser costs than the well-
established method CT-guided RFA when more than 55
patients are treated annually. As a main costs advantage,
CT-guided brachytherapy necessitates only standard
Fig. 2 A 65-year-old patient with cirrhosis and a hypervascularized, subcapsular hepatocellular carcinoma in liver segment III (a, arrow). The tumor
was ablated in a single session with 110 W over 15 min (b). The contrast-enhanced control scan obtained immediately afterwards shows
complete necrosis of the ablated area with a hypervascular rim (c, arrow)
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disposable material that is much lower in price than dedi-
cated RFA-probes, which have a relatively high price and
are only suitable for single use. This fact has never been
reported before and is important to consider, as there is
high need for cost-saving procedures in the increasingly
more expensive healthcare system.
The relatively high annual maintenance costs of 36,400
€ for the Iridium-192 source and the costs for the radi-
ation room are compensated when treating 55 patients or
more with CT-HDBRT annually.
From our own experience CT-HDBRT is feasible in
more patients, as also big tumors or tumors close to
sensitive structures can be treated where CT-RFA is lim-
ited [15, 20, 22].
The advantage of CT-guided RFA is that it can be per-
formed in one single room: planning of the procedure,
image-guided needle placement, ablation, and control of
success can be performed consecutively in one session
and in a single room within the CT scanner. As a result,
CT-RFA has a higher demand of CT in room time which
leads to higher equipment costs. Orientation during the
intervention is typically limited as it is based on CT fluor-
oscopy images where the shape of the ablation needle
defines the ablation zone. CT-HDRBT requires a more
interdisciplinary approach and more staff involved, as it is
typically a close cooperation of radiation oncologists and
interventional radiologists. Interstitial brachytherapy in
afterloading technique has to be performed in a dedicated
radiation room with special structural requirements [23],
making equipment costs higher compared to CT-RFA.
Given the more complex approach of CT-HDRBT as
Table 1 shows, it is somewhat surprising that CT-HDRBT
is can be performed at lower price than CT-RFA. This dif-
ference is mainly attributable to the high costs for dispos-
ables, namely the RFA probe, which by far tops the costs
for the sheath and brachytherapy catheters (Table 2).
Costs for other disposables are nearly the same, as both
interventions are performed in comparable settings.
It is not surprising that staff costs were higher for CT-
HDRBT than for CT-RFA as additional specialists (med-
ical physics experts and radiation oncologists) from the
radiation oncology department had to be consulted and
transfer times between different rooms had to be in-
cluded. In the setting of our hospital the interventional
radiologist has the qualification to perform brachyther-
apy which is approved by the responsible medical associ-
ation, but to make data applicable for other institutions
we included a radiation oncologist in our calculations.
Table 3 Costs for equipment for CT-HDBRT and CT-RFA
Siemens somatom
definition AS
RITA RF generator Varian medical gammamed +
planning workstation
Radiation room
Purchase Costs 670,000 19,940 135,000 400,000
Annual Maintenance 45,000 250 36,400 5,000
Depriciation Period in years 7 7 7 30
Annual Usage in min 200,000 TBDa TBDa TBDa
Proportionate Equipments Costs
CT-RFA CT-HDBRT
1 patient / year 3,098.57 74,019.05
25 patients / year 123.94 29,60.76
50 patients / year 61.97 1,480.38
100 patients /year 30.99 740.19
200 patients /year 15.49 370.10
aTBD To be determined. The annual usage was assumed to be variable, as indicated by the proportionate equipment costs in the lower part of the table
Fig. 3 Results of a sensitivity analysis comparing costs of CT-HDRBT
and CT-RFA in relation to the number of patients treated with either
method per year. The break-even is reached at 55 treated patients
per year, when calculated costs of CT-HDRBT fall below the costs of
CT-RFA. At this point, calculated costs for CT-RFA are 1,841.92 € and
1,827.89 € for CT-HDRBT, and costs for CT-HDRBT decrease further as
the number of treated patients increases, whereas costs for CT-RFA
remain nearly stable
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Fixed annual costs are higher for CT-HDRBT, as the
iridium source has to be changed every eight weeks due
to the half-life of 74 days of iridium-192 and the radi-
ation room has to depreciated [23]. During this period,
any number of patients can theoretically be treated with
one source, so the proportionate costs for the source
strongly depends on the number of patients treated per
year, as we could show in the sensitivity analysis (Fig. 3).
In general, we perform local ablations of hepatic malignan-
cies, both CT-HDRBT and CT-RFA, in conscious sedation
[16]. Only in rare cases we do use general anesthesia,
mostly when patients explicitly prefer this option. The
additional anesthetic team would raise staff and equipment
costs, but as this approach is rare with both treatment
options, we did not include these costs in our calculation.
With regard to the prices for disposables, our hospital
profits from overall low prices as we are a part of a large
purchase network of private and university hospitals.
Therefore, our purchase prices do not differ significantly
in relation to the amount of items purchased. Therefore,
the prices for disposables did not vary with regard to the
amount of consumed disposables. However, small hospi-
tals may have to pay much higher prices for high priced
disposables like RFA probes. In relative terms the use of
a therapy option like HDBRT with low costs for dispos-
ables would especially be useful for smaller hospitals in
the case they do not have the opportunity to get low
prices for high priced disposables like RFA probes as
long as their amount of consumed items is low. A break-
even for a new treatment option like HDBRT may then be
reached even with lesser patients than in our clinic as we
already profit from low purchase prices for RFA probes. In
Germany, the health care system has a dual financing [24]:
investment costs for real estates and large equipment are
borne by the federal states, and the costs directly associ-
ated with the treatment (e.g., staff costs and costs for dis-
posables) are covered by health insurance providers. For
this reason, cost for rooms are typically not in the focus of
health care providers but we had to include the radiation
room in our calculation as it is mandatory for tumor ther-
apy in afterloading technique.
Our study has limitations: The sample size of patients
treated by RFA was limited. This is because CT-HDRBT is
preferred to CT-RFA in our department – mainly because
of the subjectively higher accuracy. Reported prices and
staff costs are from the year 2015, and participation of dif-
ferent team members were reflected as they are typical in
the German health care system. In other countries, certain
activities might also be performed by other staff groups.
We are aware that both the costs for medical devices
and personnel and also the reimbursement for healthcare
services differ significantly between different countries
throughout Europe and worldwide. However, as our focus
was on relative and not absolute costs for the two different
techniques for the treatment of HCC, we expect the
main result of our cost comparison to be valid in many
different countries.
We did not take into account “overhead” costs like costs
for energy, administration, and cleaning and other rooms
beside the radiation room. The exact assessment of these
costs usually is very difficult and, as they are mainly the
same for both procedures, we did not expect them to in-
fluence the overall result.
In this context, it is arguable why we assumed an exclu-
sive utilization of the RFA generator, the radiation therapy
planning station and the brachytherapy room. We were
aware the RFA generator and the brachytherapy device
can not only be used exclusively for the two different
HCC therapy techniques but for many other indications
such as radiofrequency ablations of osteoid osteomas and
the brachytherapy of gynaecological tumors. This under-
lines the importance of interdisciplinary cooperation for
therapeutic decision making [25] and an economic and
synergetic use of the equipment.
However, this shared usage may be a major confounding
variable as especially the costs for CT-HDRBT differ sub-
stantially depending on the number of patients treated.
We could not expect that other clinics and especially pro-
viders that have to consider to begin with HDBRT will
treat the very high number of about 480 patients / year as
we do. Therefore, our own low costs for HDBRT may be
misleading for the reader. With the aim to provide a more
realistic overview of the own costs also for clinics consid-
ering to start with both procedures, we assumed that the
RFA and HDBRT equipment (which also includes the ra-
diation room) would be exclusively acquired for the two
treatments.
In contrast, most clinics nowadays have CT scanners
available which usually are intensively used for diagnostic
purposes and the use for CT-guided interventions is mostly
only in a much lesser proportion. Therefore, we did not
assume an exclusive utilization of the CT scanner for our
two CT-guided therapy options, but assumed a proportion-
ate utilization of the overall 200.000 min per year.
Finally, the prices quoted in this paper are specific to
our hospital and may differ for other hospitals. However,
the idea of the study was to give the reader a model for a
quick analysis of the own costs for the standard treatment
option of RFA and a new technique like CT-HDBRT. Per-
sonal differences in prices may easily be adapted by the
reader. In this context, we did not consider “hotel” costs
in our analysis. For both RFA and HDBRT the mean dur-
ation of a hospital stay is about 2–3 days, and it would be
easy to calculate the hospitality costs which are about 450
EUR per patient and day. As we performed a cost com-
parison with relative costs, we did not expect a difference
in these costs for both procedures and did not take “hotel”
costs into account. We also expected a significant
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variation in reimbursement for both procedures in different
countries. This is why we focused exclusively on a model to
evaluate the own costs for both procedures which can then
be compared with the individual reimbursement scheme.
Conclusion
From the provider’s perspective, the costs of CT-HDRBT
of liver lesions are much lower than those of CT-RFA
treatment as soon as at least 55 patients are treated annu-
ally. This is mainly due to relatively high fixed cost per
CT-HDRBT treatment but much lower costs for dispos-
ables compared with CT-guided RFA treatment.
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